TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2301782
Drug: Inhaled triamcinolone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone, 200 micrograms four times daily (T)
Study: 2301782
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone (T) in higher compliers
Study: 2301782
Drug: Inhaled triamcinolone
Normalized name: triamcinolone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled triamcinolone (T) in lower compliers
Study: 29115354
Drug: Daily blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily blueberry juice intake (1× dosing)
Study: 29115354
Drug: Daily blueberry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily blueberry juice intake (⅓ doses taken thrice daily)
Study: 22284248
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (esomeprazole 40 mg BID, amoxicillin 1g BID for 1 week, followed by esomeprazole 40 mg BID, levofloxacin 500 mg QD, metronidazole 500 mg TID for 1 week)
Study: 22284248
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (esomeprazole 40 mg BID, amoxicillin 1g BID, clarithromycin 500 mg BID for 2 weeks)
Study: 19148112
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy with kinesthetic stimulation (M/KS)
Study: 12095065
Drug: tazarotene plus
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tazarotene plus clindamycin phosphate lotion
Study: 9590494
Drug: IMED Gemini
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMED Gemini PC‐2TX infusion pump
Study: 3233896
Drug: Intravenous push
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous push method
Study: 8165649
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UF heparin), 10,000 IU s.c. b.d.
Study: 8165649
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (Fragmin), 5000 IU anti‐Factor Xa s.c. b.d.
Study: 21046773
Drug: Tumescent infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent infiltration solution at 25 degrees C (Group A)
Study: 21046773
Drug: Tumescent infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumescent infiltration solution at 37 degrees C (Group B)
Study: 12633119
Drug: Oral olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral olanzapine (N = 13)
Study: 12633119
Drug: Depot antipsychotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot antipsychotic control (N = 13)
Study: 10595865
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral oseltamivir
Study: 1989427
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g fish oil/d (omega-3 fatty acid)
Study: 1989427
Drug: 9 g
Normalized name: Publix Pen Needle 29 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 g corn oil/d (omega-6 fatty acid)
Study: 6349914
Drug: Cefuroxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (1 g administered 30 minutes before operation and 3 and 10 hours after)
Study: 6349914
Drug: Placebo (physiological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (physiological saline administered at the same times as cefuroxime)
Study: 17045443
Drug: Alendronate sodium
Normalized name: Alendronate Sodium
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate sodium tablets (70 mg)
Study: 11349937
Drug: Flaxseed (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (30 grams daily)
Study: 9589236
Drug: Gly‐‐>Arg substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with IGT
Study: 9589236
Drug: Gly‐‐>Arg substitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gly‐‐>Arg substitution in codon 972 of the insulin receptor substrate‐1 gene in subjects with NIDDM
Study: 7744393
Drug: Interferon 1,000,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon 1,000,000 u intramuscularly daily for 10 days
Study: 7744393
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and inosine therapy intravenously daily for 10 days
Study: 2601863
Drug: L-sulpiride 50
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride 50 mg
Study: 2601863
Drug: L-sulpiride 100
Normalized name: (±)-sulpiride
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-sulpiride 100 mg
Study: 4595974
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) 15 mg/kg/day I.V. x 5 given monthly
Study: 4595974
Drug: Fluorouracil (FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil (FU) 10 mg/kg/day I.V. on days 1 to 5; imidazole 4 carboxamide, 5 (3,3 dimethyl 1 triazeno) (ICDT) 3 mg/kg/day I.V. on days 1 and 2; vincristine (VCR) 0.025 mg/kg I.V. on day 1; bis (2 chloroethyl) 1 nitrosourea (BCNU) 1.5 mg/kg I.V. on day 1
Study: 28237263
Drug: Liraglutide 3·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3·0 mg
Study: 18835526
Drug: Ethyl pyruvate
Normalized name: ETHYL PYRUVATE
DrugBank: Ethyl pyruvate (DB05869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethyl pyruvate (EP) 7,500 mg administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg every 6 hours.
Study: 17907389
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (nilestriol 2 mg, twice/month for 3 months; medrysone 2 mg, t.i.d. for 10 days from the 3rd month)
Study: 11566440
Drug: Alcohol intake
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol intake (0.8 g/kg per day)
Study: 9193324
Drug: FAC and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAC and DZR (after 300 mg/m2 doxorubicin)
Study: 4020747
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list control group (treatment as usual)
Study: 4020747
Drug: Individual vs
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual vs Group cognitive therapy
Study: 27634158
Drug: Neurodynamic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamic treatment
Study: 23796045
Drug: Sildenafil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (3 mg/kg/day)
Study: 21598242
Drug: Combination weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination weekly docetaxel and carboplatin (cDC)
Study: 19470159
Drug: Complete CapRI-scheme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete CapRI-scheme (cisplatin, Interferon alpha-2b, external beam radiation, and three cycles of 5-fluorouracil continuous infusion)
Study: 17487762
Drug: Drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug treatment without training (Control)
Study: 6348314
Drug: diazepam, 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam, 15 to 40 mg/day
Study: 6348314
Drug: sedative-benzodiazepines (less
Approvals — FDA: no, EMA: no, PMDA: no
Description: sedative-benzodiazepines (less than eight months)
Study: 6348314
Drug: sedative-benzodiazepines (eight
Approvals — FDA: no, EMA: no, PMDA: no
Description: sedative-benzodiazepines (eight months or more)
Study: 3952641
Drug: Low-dose-rate irradiation
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose-rate irradiation (Ra226)
Study: 3952641
Drug: High-dose-rate irradiation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate irradiation (Ir192)
Study: 3952641
Drug: High-dose-rate irradiation
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose-rate irradiation (Ir192) combined with percutaneous Co60 therapy
Study: 3952641
Drug: Modified high-dose-rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified high-dose-rate irradiation (Ir192) scheme (reduction of dose from 10 to 7 Gy)
Study: 25912786
Drug: Nutrition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition therapy (intensive, biometric parameter-oriented dietary counseling)
Study: 23682433
Drug: Albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 400 mg daily for 2 days
Study: 16545120
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of exercise therapy supervised by a physical therapist
Study: 14604454
Drug: Risperidone (0.5-3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (0.5-3.0 mg/d) for 8 weeks
Study: 24205185
Drug: EPI vaccines
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI vaccines
Study: 24615194
Drug: Hypofractionated conformal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated conformal radiotherapy (RT) combined with chemotherapy (CHT)
Study: 20862644
Drug: Paroxetine (dose-escalation)
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paroxetine (dose-escalation)
Study: 20862644
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose of SSRIs
Study: 17823083
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride (60 mg/day)
Study: 11837381
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg valsartan tablet
Study: 11837381
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 160 mg valsartan capsules
Study: 10214735
Drug: Controlled-release physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release physostigmine 30 mg daily
Study: 10214735
Drug: Controlled-release physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release physostigmine 36 mg daily
Study: 10214735
Drug: Controlled-release physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release physostigmine (both dosages)
Study: 7609260
Drug: Voucher incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher incentive strategy (family returns monthly for WIC food vouchers until child is immunized)
Study: 2649811
Drug: Yuzpe's postcoital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yuzpe's postcoital method (0.1 mg ethinyloestradiol and 1 mg d1‐norgestrel taken within 72 hours of unprotected intercourse and repeated 12 hours later)
Study: 2649811
Drug: Levonorgestrel pills
Normalized name: levonorgestrel Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel pills
Study: 367425
Drug: Methyldopa treatment
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa treatment for hypertension in pregnancy
Study: 28135846
Drug: Lithium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium monotherapy (N=49)
Study: 28135846
Drug: Sertraline monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline monotherapy (N=45)
Study: 28135846
Drug: Lithium/Sertraline combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium/Sertraline combination (N=48)
Study: 28135846
Drug: Lithium/Sertraline combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium/Sertraline combination
Study: 27557302
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg per kilogram of body weight) in combination with bortezomib (1.3 mg per square meter) and dexamethasone (20 mg)
Study: 27557302
Drug: Bortezomib (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1.3 mg per square meter) and dexamethasone (20 mg) alone
Study: 17284894
Drug: Dextromethorphan (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (90 mg)
Study: 11564000
Drug: Rebamipide 100
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 100 mg, three times a day for 8 weeks
Study: 11564000
Drug: Rebamipide 200
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 200 mg, three times a day for 8 weeks
Study: 11564000
Drug: Rebamipide 100
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebamipide 100 mg
Study: 11564000
Drug: Rebamipide 200
Normalized name: Rébamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 200 mg
Study: 3664914
Drug: nalbuphine 20
Normalized name: nalbuphine 20 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 20 mg IV
Study: 3664914
Drug: nalbuphine 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nalbuphine 40 mg IV
Study: 3664914
Drug: meperidine 75
Normalized name: MEPERIDINE 75MG/ML INJ CARPUJECT LL 1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: meperidine 75 mg IM
Study: 29471865
Drug: NECT (nifurtimox-eflornithine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NECT (nifurtimox-eflornithine combination) - 200 mg/kg eflornithine infusions every 12 hours for 7 days and 8 hourly oral nifurtimox at 5 mg/kg for 10 days
Study: 29471865
Drug: Eflornithine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eflornithine monotherapy - 100 mg/kg every 6 hours for 14 days
Study: 8647515
Drug: Fluconazole 300
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluconazole 300 mg/day
Study: 8647515
Drug: Fluconazole 50
Normalized name: fluconazole 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 50 mg/day (control)
Study: 24563
Drug: Ketotifen 1
Normalized name: ketotifen 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 1 mg b.i.d. (Group I)
Study: 24563
Drug: Ketotifen 2
Normalized name: ketotifen 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen 2 mg b.i.d. (Group II)
Study: 24563
Drug: Clemastine 1
Normalized name: clemastine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clemastine 1 mg b.i.d. (Group III)
Study: 30586575
Drug: Exendin-9,39 infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exendin-9,39 infusion at 300 pmol/kg/min for 6 h
Study: 28779304
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy (10 sessions over 2 weeks, 5 sessions a week)
Study: 28779304
Drug: Peloid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peloid therapy vs Control group
Study: 17919093
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy, counseling, and self-help written materials
Study: 14758135
Drug: 5 years
Normalized name: Dymadon 5 Years Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 years of tamoxifen after CNF chemotherapy and ovarian ablation (Group B)
Study: 14758135
Drug: CNF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNF chemotherapy
Study: 11708731
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality treatment
Study: 7928850
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (25 mg of Zn and 1.5 mg of copper)
Study: 1092511
Drug: Amitriptyline in
Normalized name: amitriptyline Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline in combination with alcohol (0.5 gm/kg)
Study: 1092511
Drug: Doxepin in
Normalized name: doxepin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin in combination with alcohol (0.5 gm/kg)
Study: 1092511
Drug: Amitriptyline and
Normalized name: amitriptyline and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline and Doxepin in combination with alcohol (0.5 gm/kg)
Study: 28637922
Drug: Lampalizumab administered
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lampalizumab administered by intravitreal injection monthly
Study: 28637922
Drug: Lampalizumab administered
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lampalizumab administered by intravitreal injection every other month
Study: 28637922
Drug: Lampalizumab (monthly)
Normalized name: Natalizumab
DrugBank: Lampalizumab (DB11826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lampalizumab (monthly) in CFI risk-allele carriers
Study: 22612171
Drug: Concurrent motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent motor tasks
Study: 22612171
Drug: Concurrent verbal
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent verbal tasks
Study: 22612171
Drug: Concurrent visual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent visual tasks
Study: 15317602
Drug: Nateglinide (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (90 mg)
Study: 9390981
Drug: High-dose creatine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose creatine intake (20 g/day) for 4 days followed by low-dose creatine intake (5 g/day) during 10 weeks of training
Study: 9390981
Drug: Low-dose creatine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose creatine intake (5 g/day) during 10 weeks of training
Study: 9390981
Drug: Low-dose creatine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose creatine intake (5 g/day) during 10 weeks of detraining
Study: 7517058
Drug: Aprotinin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (2 x 10(6) KIU upon anesthetic induction, similar dose in the priming pump, maintenance dose of 500,000 KIU/h)
Study: 22527327
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections (mean number of 5.0 injections) in patients with SMD
Study: 22527327
Drug: Intravitreal ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal ranibizumab injections (mean number of 4.3 injections) in patients without SMD
Study: 14629706
Drug: Individualized dose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized dose regimen of amitriptyline (n = 30) for 8 weeks
Study: 14629706
Drug: Empiric dose
Normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric dose regimen of amitriptyline (n = 30) for 8 weeks
Study: 8093291
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60 mg retinol equivalent)
Study: 2436856
Drug: Ringer's acetate‐gluconate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate‐gluconate solution (56 +/- 15 ml/kg)
Study: 2436856
Drug: 6% dextran‐70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% dextran‐70 (16 +/- 6 ml/kg)
Study: 31069459
Drug: Probiotic yoghurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yoghurt (100 g/day from 24 weeks of gestation until delivery)
Study: 21194827
Drug: Hyoscine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine (10 mg)
Study: 16446007
Drug: Propionyl l-carnitine
Normalized name: glycine propionyl-L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl l-carnitine (PLC) 2 g/day
Study: 12522753
Drug: Investigational antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational antiretroviral agents
Study: 25089881
Drug: Dimension cues
Normalized name: DIMENSION
DrugBank: Dithiopyr (DB15230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimension cues indicating the relevant stimulus dimension (e.g., 'number')
Study: 25089881
Drug: Mapping cues
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mapping cues providing information regarding both the relevant task identity and its category-to-key mapping (e.g., 'one three')
Study: 25089881
Drug: Neutral Stroop
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral Stroop condition (name color patches, low control demand)
Study: 20105610
Drug: Initial nonoperative
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial nonoperative management (intravenous antibiotics with percutaneous drainage followed by interval laparoscopic appendectomy)
Study: 17284750
Drug: Watercress supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Watercress supplementation (85 g raw watercress daily for 8 weeks)
Study: 11972998
Drug: Dextromethorphan 100
Normalized name: guaifenesin/dextromethorphan 100 mg-10 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 100 mg
Study: 10442377
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 to 400 mg/day for 2 years)
Study: 10442377
Drug: UFT (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (600 mg/day)
Study: 10442377
Drug: UFT (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (300 mg/day)
Study: 2207297
Drug: Recainam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (oral doses 54-208 mg kg-1 in mice)
Study: 2207297
Drug: Recainam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (oral doses 25-110 mg kg-1 in rats)
Study: 2207297
Drug: Recainam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (oral doses 50-100 mg kg-1 in rabbits)
Study: 2207297
Drug: Recainam (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (i.v. doses 1-15 mg kg-1 in rhesus monkeys)
Study: 2207297
Drug: Recainam (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (oral doses 6-60 mg kg-1 in dogs)
Study: 2207297
Drug: Recainam (400-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (400-800 mg in humans)
Study: 2207297
Drug: Recainam (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recainam (single or multiple doses in dogs)